The pharmaceuticals company Glenmark Pharma Ltd introduce medicine for the time with the combination of Teneligliptin (20mg) and Dapagliflozin (5mg/10mg) for the treatment of adult patients with type two diabetes, especially the ones with comorbidities.
- Mumbai Office Leasing and Residential Sales Grow in 2024
- Nvidia Launches New RTX 50 Series GPU
- Consint.AI Secures Rs 5 Crore Funding in Seed Round
- Arkade Developers Adds 3 New Redevelopment Projects
- India Launches a New Steel PLI Scheme
‘Zita D’ which contains Teneligliptin (20mg) andDapagliflozin (5 mg/10 mg). This medicine can be consumed by the patient once a day daily as per prescription, which helps to improve glycemic control and prevent complications in adult patients with type two diabetes, especially the ones with comorbidities, as per the statement said.
